高级检索

替格瑞洛对行经皮冠状动脉介入治疗的急性非ST段抬高型心肌梗死患者的疗效

Effect of ticagrelor for acute non-ST-segment elevation myocardial infarction patents underwent percutaneous coronary intervention

    摘要
  • 摘要:
      目的  探讨替格瑞洛对经皮冠状动脉介入治疗(PCI)对急性非ST段抬高型心肌梗死(NSTEMI)患者的效果。
      方法  选取本院心内科收治的240例行PCI术治疗的NSTEMI患者，根据随机数表法分为替格瑞洛组(n=120)和氯吡格雷组(n=120), 检测2组PCI前后血清白细胞介素-6(IL-6)、C反应蛋白(CRP)水平以及血小板聚集率，比较2组PCI术后30 d不良心血管事件(MACE)发生情况。
      结果  PCI术前, 2组血小板聚集率、血清IL-6、CRP水平比较差异无统计学意义(P>0.05); PCI术后1、7、30 d, 替格瑞洛组血小板聚集率和血清IL-6、CRP水平均低于氯吡格雷组，差异有统计学意义(P < 0.05); 替格瑞洛组PCI术后30 d内MACE发生率显著低于氯吡格雷组(P < 0.05)。
      结论  替格瑞洛抗血小板聚集和抗炎作用优于氯吡格雷组，能够显著降低NSTEMI介入治疗患者的MACE发生风险，并改善预后。

     

    Abstract:
      Objective  To investigate the effect of ticagrelor on acute non-ST-segment elevation myocardial infarction (NSTEMI) after percutaneous coronary intervention (PCI).
      Methods  A total of 240 patients with NSTEMI treated by PCI were randomly divided into Ticagrelor group (n=120) and clopidogrel group (n=120). Serum levels of interleukin-6 (IL-6), C reactive protein (CRP) and platelet aggregation rate were measured before and after PCI. The incidence of adverse cardiovascular events (MACE) at 30 days after PCI was compared between the two groups.
      Results  There were no significant differences in platelet aggregation rate, serum IL-6 and CRP levels between the two groups before PCI (P>0.05). The platelet aggregation rate, serum IL-6 and CRP levels in tigrillo group were significantly lower than those in clopidogrel group at 1, 7, 30 d after PCI (P < 0.05). The incidence of MACE was significantly lower than that of clopidogrel group (P < 0.05).
      Conclusion  Tigrillo has better anti-platelet aggregation and anti-inflammatory effects than clopidogrel, which can significantly reduce the risk of MACE and improve the prognosis of patients withNSTEMI interventional therapy.

     

    • HTML全文
    • 参考文献(15)
    • 相关文章
    • 施引文献
  • 资源附件(0)

/

返回文章
返回